vitamin D2What was measured
Measured, with no finding
344 endpoints
Show what was measuredHide what was measured
absolute change in serum 25(OH)D concentration from baseline, vitamin D2 versus vitamin D3, weighted mean difference, random effects
decreases, WMD 15.23 nmol/L (95% CI 6.12, 24.34) favouring cholecalciferol over ergocalciferol, p = 0.001
Not recorded as a finding: the comparison was against another active treatment
With the use of a random-effects model, overall, there was a significantly greater effect in the raising of serum 25(OH)D concentrations over time for D3 supplementation than for D2 supplementation (mean difference: 15.23; 95% CI: 6.12, 24.34; P = 0.001).
PMID 22552031 · one of two readings recorded this
absolute change in serum 25(OH)D from baseline (nmol/L), vitamin D2 versus vitamin D3, overall and by daily versus bolus dosing
cholecalciferol minus ergocalciferol WMD 15.23 nmol/L (95% CI 6.12, 24.34), p = 0.001
Not recorded as a finding: the comparison was against another active treatment
Overall, the analysis showed that the greater absolute change in serum 25(OH)D from baseline favored the cholecalciferol intervention, with a weighted mean difference of 15.23 (95% CI: 6.12, 24.34; Z = 3.28; P = 0.001).
PMID 22552031 · one of two readings recorded this
Change in serum 25(OH)D from baseline
increases, p = 0.001
the greater absolute change in serum 25(OH)D from baseline favored the cholecalciferol intervention, with a weighted mean difference of 15.23 (95% CI: 6.12, 24.34; Z = 3.28; P = 0.001)
PMID 22552031 · one of two readings recorded this
Change in serum 25(OH)D from baseline
increases, p = 0.0002
Three of these studies had data available that showed that bolus doses favored cholecalciferol with a weighted mean difference of 34.10 (95% CI: 16.38, 51.83; Z = 3.77; P = 0.0002)
PMID 22552031 · one of two readings recorded this
Change in serum 25(OH)D from baseline
no effect, p = 0.1
the result was nonsignificant with a weight mean difference of 4.83 (95% CI: −0.98, 10.64; Z = 1.63; P = 0.10)
PMID 22552031 · one of two readings recorded this
Serum 25(OH)D concentration
no effect, n = 68
Holick et al, 2008; United States | 1) Placebo | 68 | 47 F | 11 wk | At the end of the intervention, there was no significant difference in 25(OH)D concentrations between vitamin D2 and D3 groups.
PMID 22552031 · one of two readings recorded this
Serum 25(OH)D increase
increases, n = 69
Leventis and Kiely 2009; United Kingdom | Study 1: single intramuscular injection of 300,000 IU vitamin D2 | 69 | Study 1: 43 F and 7 M | 24 wk | Greater increases in serum 25(OH)D were achieved with vitamin D3 intervention
PMID 22552031 · one of two readings recorded this
Serum 25(OH)D increase
increases, p = 0.01, n = 70
Glendenning et al, 2009; Australia | 1) Ergocalciferol 1000 IU/d | 70 | Sex | 3 mo | Vitamin D3 supplementation was associated with a 31% greater increase in concentrations of serum 25(OH)D than was vitamin D2 supplementation (P = 0.01).
PMID 22552031 · one of two readings recorded this
Serum 25(OH)D increase
increases, n = 19
Tjellesen et al, 1986; Denmark | 1) 4000 IU vitamin D3 2) 4000 IU vitamin D2 | 19 | All F22–49 y | 8 wk | Vitamin D3 was linked to a greater increase in serum 25(OH)D compared with that in the vitamin D2 intervention group. No direct statistical comparison results were available.
PMID 22552031 · one of two readings recorded this
Serum 25(OH)D increase
increases, p = 0.03, n = 89
Trang et al, 1998; Canada | 1) Untreated 2) 4000 IU vitamin D2 3) 4000 IU vitamin D3 | 89 | 48 F23 M18 Unknown38 ± 9 y | 14 d | Greater increase in serum 25(OH)D concentrations with vitamin D3 group than with vitamin D2 group (P = 0.03).
PMID 22552031 · one of two readings recorded this
All-cause mortality
decreases, p = 0.02
Vitamin D decreased mortality in all 56 trials analysed together (5,920/47,472 (12.5%) vs 6,077/47,814 (12.7%); RR 0.97 (95% confidence interval (CI) 0.94 to 0.99); P = 0.02
PMID 24414552 · one of two readings recorded this
All-cause mortality
decreases, p = 0.002, n = 75927
only vitamin D3 decreased mortality (4,153/37,817 (11.0%) vs 4,340/38,110 (11.4%); RR 0.94 (95% CI 0.91 to 0.98); P = 0.002; I(2) = 0%; 75,927 participants; 38 trials
PMID 24414552 · one of two readings recorded this
Cancer mortality
decreases, p = 0.02, n = 44492
Vitamin D3 statistically significantly decreased cancer mortality (RR 0.88 (95% CI 0.78 to 0.98); P = 0.02; I(2) = 0%; 44,492 participants; 4 trials
PMID 24414552 · one of two readings recorded this
Hypercalcaemia
increases, p = 0.02, n = 710
Alfacalcidol and calcitriol increased the risk of hypercalcaemia (RR 3.18 (95% CI 1.17 to 8.68); P = 0.02; I(2) = 17%; 710 participants; 3 trials
PMID 24414552 · one of two readings recorded this
Nephrolithiasis
increases, p = 0.02, n = 42876
Vitamin D3 combined with calcium increased the risk of nephrolithiasis (RR 1.17 (95% CI 1.02 to 1.34); P = 0.02; I(2) = 0%; 42,876 participants; 4 trials
PMID 24414552 · one of two readings recorded this
Number needed to treat to prevent one additional death (trial sequential analysis, vitamin D3)
decreases
corresponding to 150 people treated over five years to prevent one additional death
PMID 24414552 · one of two readings recorded this
Cardiovascular mortality
increases
were 1.35 (95% confidence interval 1.13 to 1.61) for death from cardiovascular disease (6416 events)
PMID 24690623 · one of two readings recorded this
all-cause mortality in randomised trials of vitamin D2 supplementation given alone versus placebo or no treatment (eight trials), random-effects pooled risk ratio
Not recorded as a finding: the direction is carried only as a signed number
The corresponding risk ratios according to type of vitamin D supplementation was 0.89 (0.80 to 0.99) for vitamin D3 and 1.04 (0.97 to 1.11) for vitamin D2 (fig 6).
PMID 24690623 · one of two readings recorded this
all-cause mortality, pooled risk ratio, vitamin D2 supplementation alone versus placebo or no treatment (208 to 4500 IU/day, eight trials)
Not recorded as a finding: the direction is carried only as a signed number
The corresponding risk ratios according to type of vitamin D supplementation was 0.89 (0.80 to 0.99) for vitamin D3 and 1.04 (0.97 to 1.11) for vitamin D2 (fig 6).
PMID 24690623 · one of two readings recorded this
All cause mortality
no effect
a total of 2527 all cause mortality events occurred among participants in the intervention group compared with 2587 events in the control group, with a combined risk ratio of 0.98 (0.94 to 1.02) in all studies
PMID 24690623 · one of two readings recorded this
All cause mortality
no effect
The corresponding risk ratios according to type of vitamin D supplementation was 0.89 (0.80 to 0.99) for vitamin D3 and 1.04 (0.97 to 1.11) for vitamin D2 (fig 6)
PMID 24690623 · one of two readings recorded this
All cause mortality
decreases
The corresponding risk ratios according to type of vitamin D supplementation was 0.89 (0.80 to 0.99) for vitamin D3 and 1.04 (0.97 to 1.11) for vitamin D2 (fig 6)
PMID 24690623 · one of two readings recorded this
All cause mortality
increases
1.35 (1.22 to 1.49) for all cause mortality (48 488 events)
PMID 24690623 · one of two readings recorded this
All cause mortality
increases
each 10 ng/mL decline of 25-hydroxyvitamin D concentration was associated with a 16% (95% confidence interval 8% to 23%) increased risk of all cause mortality
PMID 24690623 · one of two readings recorded this
Cancer mortality
increases
1.14 (1.01 to 1.29) for death from cancer (5003 events)
PMID 24690623 · one of two readings recorded this
Estimated absolute risk difference for all cause mortality associated with vitamin D deficiency
were 75.4 events in Europe and 96.6 events in the United States, per 100 000 population, per year
PMID 24690623 · one of two readings recorded this
Other non-vascular, non-cancer mortality
increases
1.30 (1.07 to 1.59) for other non-vascular, non-cancer death (1444 events)
PMID 24690623 · one of two readings recorded this
Prevalence of severe deficiency (25(OH)D <10 ng/mL) in general population
using 25-hydroxyvitamin D concentrations less than 10 ng/mL as the criterion, 4% and 15% of the general population were severely deficient in the Europe and United States, respectively
PMID 24690623 · one of two readings recorded this
Prevalence of vitamin D insufficiency (25(OH)D <30 ng/mL)
86.4% (78.4% to 95.2%) for Europe
PMID 24690623 · one of two readings recorded this
Prevalence of vitamin D insufficiency (25(OH)D <30 ng/mL)
the prevalence of vitamin D insufficiency (defined as 25-hydroxyvitamin D concentration <30 ng/mL) was 69.5% (95% confidence interval 62.1% to 77.7%) for the United States
PMID 24690623 · one of two readings recorded this
Proportion of all deaths attributable to vitamin D deficiency
9.4% of all deaths in Europe and 12.8% of those in the United States could be attributed to vitamin D deficiency
PMID 24690623 · one of two readings recorded this
All-cause mortality
decreases, p = 0.009
Vitamin D decreased all-cause mortality (1854/24,846 (7.5%) versus 2007/25,020 (8.0%); RR 0.93 (95% CI 0.88 to 0.98); P = 0.009
PMID 24953955 · one of two readings recorded this
Cancer mortality
decreases, p = 0.02
Vitamin D₃ decreased cancer mortality (558/22,286 (2.5%) versus 634/22,206 (2.8%); RR 0.88 (95% CI 0.78 to 0.98); P = 0.02
PMID 24953955 · one of two readings recorded this
cancer occurrence, all-cause mortality, cancer mortality and nephrolithiasis for vitamin D supplementation pooled across vitamin D3 (14 trials), vitamin D2 (1 trial) and calcitriol (3 trials); no vitamin D2-specific estimate in the abstract
no effect, p = 0.88, n = 50623
Not recorded as a finding: another reason, stated per paper
Cancer occurrence was observed in 1927/25,275 (7.6%) recipients of vitamin D versus 1943/25,348 (7.7%) recipients of control interventions (RR 1.00 (95% confidence interval (CI) 0.94 to 1.06); P = 0.88; I² = 0%; 18 trials; 50,623 participants; moderate quality evidence according to the GRADE instrument).
PMID 24953955 · one of two readings recorded this
Cancer occurrence
no effect, p = 0.88
Cancer occurrence was observed in 1927/25,275 (7.6%) recipients of vitamin D versus 1943/25,348 (7.7%) recipients of control interventions (RR 1.00 (95% confidence interval (CI) 0.94 to 1.06); P = 0.88
PMID 24953955 · one of two readings recorded this
Cancer occurrence
no effect, p = 0.88
Cancer occurrence was observed in 1918/24,908 (7.7%) recipients of vitamin D₃ versus 1933/24,983 (7.7%) in recipients of control interventions (RR 1.00 (95% CI 0.94 to 1.06); P = 0.88
PMID 24953955 · one of two readings recorded this
Nephrolithiasis
increases, p = 0.02
Vitamin D₃ combined with calcium increased nephrolithiasis (RR 1.17 (95% CI 1.03 to 1.34); P = 0.02
PMID 24953955 · one of two readings recorded this
HDL cholesterol
decreases
In the D2 group there were small, but statistically significant, decreases from baseline relative to placebo in total cholesterol and ApoB (favouring D2), as well as in HDL cholesterol and ApoA1 (favouring placebo; Figure 4A)
PMID 26700109 · one of two readings recorded this
apolipoprotein A1
decreases
In the D2 group there were small, but statistically significant, decreases from baseline relative to placebo in total cholesterol and ApoB (favouring D2), as well as in HDL cholesterol and ApoA1 (favouring placebo; Figure 4A)
PMID 26700109 · one of two readings recorded this
25(OH)D2 change from baseline
increases
in the D2 group, the mean 25(OH)D2 concentration increased by 48.7 (19.2) nmol/l, while the 25(OH)D3 concentration decreased by 17.5 (22.1) nmol/l, and total 25(OH)D concentration increased by 31.2 (28.6) nmol/l
PMID 26700109 · one of two readings recorded this
25(OH)D3 change from baseline
decreases
in the D2 group, the mean 25(OH)D2 concentration increased by 48.7 (19.2) nmol/l, while the 25(OH)D3 concentration decreased by 17.5 (22.1) nmol/l, and total 25(OH)D concentration increased by 31.2 (28.6) nmol/l
PMID 26700109 · one of two readings recorded this
25(OH)D3 change from baseline
increases
25(OH)D3 and total 25(OH)D concentrations increased by 38.3 (24.2) nmol/l and 38.1 (23.8) nmol/l, respectively
PMID 26700109 · one of two readings recorded this
anthropometric measures, blood pressure, hsCRP, CVD risk, hepatic markers, fructosamine
no effect
Among the secondary outcomes, there were no differences comparing D2 with placebo or D3 with placebo for anthropometric measures, blood pressure, hsCRP, CVD risk, assessed by UKPDS risk engine, hepatic markers, or fructosamine
PMID 26700109 · one of two readings recorded this
apolipoprotein B
decreases
In the D2 group there were small, but statistically significant, decreases from baseline relative to placebo in total cholesterol and ApoB (favouring D2), as well as in HDL cholesterol and ApoA1 (favouring placebo; Figure 4A)
PMID 26700109 · one of two readings recorded this
apolipoprotein B
decreases
In the D3 group, there was a very small decrease in ApoB concentration between baseline and follow‐up relative to placebo
PMID 26700109 · one of two readings recorded this
fructosamine difference (post hoc)
no effect
D3 versus D2: −2.94 (95% CI −8.37, 2.48) µmol/l
PMID 26700109 · one of two readings recorded this
HbA1c change from baseline (mmol/mol)
no effect, p = 0.13
the difference comparing D2 with placebo was −0.05% (95% CI −0.11, 0.02) or −0.51 (95% CI −1.16, 0.14) mmol/mol (p = 0.13)
PMID 26700109 · one of two readings recorded this
HbA1c change from baseline (mmol/mol)
no effect, p = 0.57
for D3 versus placebo it was 0.02% (95% CI −0.04%, 0.08%) or 0.19 (95% CI −0.46, 0.83) mmol/mol (p = 0.57)
PMID 26700109 · one of two readings recorded this
HbA1c change from baseline (%)
no effect, p = 0.13
the difference comparing D2 with placebo was −0.05% (95% CI −0.11, 0.02) or −0.51 (95% CI −1.16, 0.14) mmol/mol (p = 0.13)
PMID 26700109 · one of two readings recorded this
HbA1c change from baseline (%)
no effect, p = 0.57
for D3 versus placebo it was 0.02% (95% CI −0.04%, 0.08%) or 0.19 (95% CI −0.46, 0.83) mmol/mol (p = 0.57)
PMID 26700109 · one of two readings recorded this
HbA1c difference (mmol/mol)
no effect
there was no evidence of a treatment effect [D3 vs D2: 0.06% (95%CI −0.005, 0.13%) or 0.66 (95% CI −0.05, 1.38) mmol/mol]
PMID 26700109 · one of two readings recorded this
HbA1c difference (%)
no effect
there was no evidence of a treatment effect [D3 vs D2: 0.06% (95%CI −0.005, 0.13%) or 0.66 (95% CI −0.05, 1.38) mmol/mol]
PMID 26700109 · one of two readings recorded this
parathyroid hormone, serum
no effect
Not recorded as a finding: no_outcome_node: no parathyroid hormone node
There was an increase in PTH in the D2 group, but the difference between D2 and placebo was not statistically significant.
PMID 26700109 · one of two readings recorded this
parathyroid hormone
no effect
There was an increase in PTH in the D2 group, but the difference between D2 and placebo was not statistically significant
PMID 26700109 · one of two readings recorded this
parathyroid hormone
decreases
There was a decrease in PTH in the D3 group between baseline and follow‐up that was significantly different from the increase seen in the placebo group
PMID 26700109 · one of two readings recorded this
proportion with 25(OH)D <50 nmol/l at baseline
The percentages of individuals with a 25(OH)D concentration <50 nmol/l at baseline were 58.8, 50.9 and 50.9% in the placebo, D2 and D3 groups, respectively
PMID 26700109 · one of two readings recorded this
proportion with 25(OH)D <50 nmol/l at baseline
The percentages of individuals with a 25(OH)D concentration <50 nmol/l at baseline were 58.8, 50.9 and 50.9% in the placebo, D2 and D3 groups, respectively
PMID 26700109 · one of two readings recorded this
proportion with 25(OH)D <50 nmol/l at baseline
The percentages of individuals with a 25(OH)D concentration <50 nmol/l at baseline were 58.8, 50.9 and 50.9% in the placebo, D2 and D3 groups, respectively
PMID 26700109 · one of two readings recorded this
proportion with 25(OH)D <50 nmol/l at follow-up
decreases
at follow‐up these percentages were 47.3, 4.5 and 3.5%
PMID 26700109 · one of two readings recorded this
proportion with 25(OH)D <50 nmol/l at follow-up
decreases
at follow‐up these percentages were 47.3, 4.5 and 3.5%
PMID 26700109 · one of two readings recorded this
proportion with 25(OH)D <50 nmol/l at follow-up
at follow‐up these percentages were 47.3, 4.5 and 3.5%
PMID 26700109 · one of two readings recorded this
pulse wave velocity change from baseline
decreases
in both the D2 [mean (s.d.) −0.17 (2.5) m/s] and D3 [mean (s.d.) −0.75 (2.1) m/s] groups
PMID 26700109 · one of two readings recorded this
pulse wave velocity change from baseline
decreases
in both the D2 [mean (s.d.) −0.17 (2.5) m/s] and D3 [mean (s.d.) −0.75 (2.1) m/s] groups
PMID 26700109 · one of two readings recorded this
pulse wave velocity, handheld Doppler carotid-femoral, treatment difference versus placebo
decreases, D2 vs placebo -0.68 m/s (95% CI -1.31, -0.05)
Not recorded as a finding: endpoint_near_miss: carotid-femoral PWV node specifies applanation tonometry or a validated oscillometric device; the paper used handheld ultrasonic Doppler velocimeters, and the segment is stated so the unspecified-segment node does not fit either
There was a reduction from baseline in PWV in both the D2 [mean (s.d.) −0.17 (2.5) m/s] and D3 [mean (s.d.) −0.75 (2.1) m/s] groups, relative to placebo [treatment difference D2 vs placebo: −0.68 (95% CI −1.31,−0.05) m/s; D3 vs placebo: −0.73 (95% CI −1.42, −0.03) m/s; Figure 4A, B].
PMID 26700109 · one of two readings recorded this
pulse wave velocity treatment difference vs placebo
decreases
treatment difference D2 vs placebo: −0.68 (95% CI −1.31,−0.05) m/s; D3 vs placebo: −0.73 (95% CI −1.42, −0.03) m/s
PMID 26700109 · one of two readings recorded this
pulse wave velocity treatment difference vs placebo
decreases
the treatment differences were −0.79 (95% CI −1.43, −0.14) m/s for D2 versus placebo, and −1.01 (95% CI −1.69, −0.34) m/s for D3 versus placebo
PMID 26700109 · one of two readings recorded this
pulse wave velocity treatment difference vs placebo
decreases
treatment difference D2 vs placebo: −0.68 (95% CI −1.31,−0.05) m/s; D3 vs placebo: −0.73 (95% CI −1.42, −0.03) m/s
PMID 26700109 · one of two readings recorded this
pulse wave velocity treatment difference vs placebo
decreases
the treatment differences were −0.79 (95% CI −1.43, −0.14) m/s for D2 versus placebo, and −1.01 (95% CI −1.69, −0.34) m/s for D3 versus placebo
PMID 26700109 · one of two readings recorded this
serum 25(OH)D2
increases
Mean (s.d.) 25(OH)D2 concentrations increased in the D2 group from 5.2 (4.1) nmol/l to 53.9 (18.5) nmol/l
PMID 26700109 · one of two readings recorded this
serum 25(OH)D3
increases
mean (s.d.) 25(OH)D3 concentrations increased from 45.8 (22.6) nmol/l to 83.8 (22.7) nmol/l in the D3 group
PMID 26700109 · one of two readings recorded this
total 25(OH)D change from baseline
increases
in the D2 group, the mean 25(OH)D2 concentration increased by 48.7 (19.2) nmol/l, while the 25(OH)D3 concentration decreased by 17.5 (22.1) nmol/l, and total 25(OH)D concentration increased by 31.2 (28.6) nmol/l
PMID 26700109 · one of two readings recorded this
total 25(OH)D change from baseline
increases
25(OH)D3 and total 25(OH)D concentrations increased by 38.3 (24.2) nmol/l and 38.1 (23.8) nmol/l, respectively
PMID 26700109 · one of two readings recorded this
total cholesterol
decreases
In the D2 group there were small, but statistically significant, decreases from baseline relative to placebo in total cholesterol and ApoB (favouring D2), as well as in HDL cholesterol and ApoA1 (favouring placebo; Figure 4A)
PMID 26700109 · one of two readings recorded this
blood pressure between groups
no effect, p = 0.941
Of note, there was no significant difference in blood pressure between groups at 12-month follow-up (P = 0.941)
PMID 26711179 · one of two readings recorded this
left atrial volume change
increases, p = 0.0025
In the placebo group, left atrial volume significantly increased on follow-up (LA volume increased 6.3 mL, P = 0.0025)
PMID 26711179 · one of two readings recorded this
left atrial volume change
no effect, p = 0.29
Compared with placebo group, the treatment group with ergocalciferol had attenuated increases in left atrial volume (LA volume increased 2.6 mL, P = 0.29)
PMID 26711179 · one of two readings recorded this
left atrial volume, echocardiography biplane Simpson's method, change over 12 months
decreases
Not recorded as a finding: no_outcome_node: no left atrial volume node; the listed LVEF and E/e' nodes are different measures
Compared with placebo group, the treatment group with ergocalciferol had attenuated increases in left atrial volume (LA volume increased 2.6 mL, P = 0.29).
PMID 26711179 · one of two readings recorded this
left ventricular ejection fraction and wall thickness
no effect
Left ventricular ejection fraction and wall thickness did not change significantly in either group, as well as parameters evaluating diastolic function (IVRT, DT, septal E′, lateral E′)
PMID 26711179 · one of two readings recorded this
serum 25(OH)D at 12 months
increases, p = 0.001
At 12 months, the mean serum 25(OH) vit D level had increased to 50.5 ± 24.1 ng/mL in the treatment group and to 20.18 ± 9.6 ng/mL in the placebo group (between groups P < 0.001)
PMID 26711179 · one of two readings recorded this
serum 25(OH)D at 12 months
increases
At 12 months, the mean serum 25(OH) vit D level had increased to 50.5 ± 24.1 ng/mL in the treatment group and to 20.18 ± 9.6 ng/mL in the placebo group (between groups P < 0.001)
PMID 26711179 · one of two readings recorded this
baseline free 25D
no effect, p = 0.8
Baseline total (22.2 ± 3.3 vs 23.3 ± 7.2 ng/mL; P = .5) and free (5.4 ± 0.8 vs 5.3 ± 1.7 pg/mL; P = .8) 25D levels were similar between D2 and D3 groups
PMID 27192696 · one of two readings recorded this
baseline total 25D
no effect, p = 0.5
Baseline total (22.2 ± 3.3 vs 23.3 ± 7.2 ng/mL; P = .5) and free (5.4 ± 0.8 vs 5.3 ± 1.7 pg/mL; P = .8) 25D levels were similar between D2 and D3 groups
PMID 27192696 · one of two readings recorded this
increase in free 25D
increases, p = 0.02
and free (+3.6 vs +6.2 pg/mL; P = .02) 25D levels were greater with D3 vs D2
PMID 27192696 · one of two readings recorded this
increase in total 25D
increases, p = 0.001
Increases in total (+27.6 vs +12.2 ng/mL; P = .001)
PMID 27192696 · one of two readings recorded this
percentage change in iPTH association with change in free 25D
unclear
Percentage change in iPTH was significantly associated with change in free (but not total) 25D, without and with adjustment for supplementation regimen, change in 1,25-dihydroxyvitamin D, and change in calcium
PMID 27192696 · one of two readings recorded this
serum total 25(OH)D and directly measured free 25(OH)D, change from baseline to 10 weeks, vitamin D2 versus vitamin D3 at 50,000 IU twice weekly for 5 weeks
decreases
Not recorded as a finding: the comparison was against another active treatment
D3 increased total and free 25D levels to a greater extent than D2.
PMID 27192696 · one of two readings recorded this
25(OH)D AUC140 (adjusted for sex, BMI, baseline 25(OH)D)
increases, p = 0.001
AUC from day 0 to 140 (AUC140) of 25(OH)D was 40% (D3 daily) to 55% (D3 2-weekly) higher with active-treatment than placebo (p < 0.001)
PMID 28231782 · one of two readings recorded this
25(OH)D AUC140 (adjusted for sex, BMI, baseline 25(OH)D)
increases, p = 0.001
AUC from day 0 to 140 (AUC140) of 25(OH)D was 40% (D3 daily) to 55% (D3 2-weekly) higher with active-treatment than placebo (p < 0.001)
PMID 28231782 · one of two readings recorded this
25(OH)D2 AUC140
increases, p = 0.001
25(OH)D2 AUC140 was higher in daily than 2-weekly (17%, p = 0.006) and 4-weekly (20%, p = 0.001) D2-treated groups
PMID 28231782 · one of two readings recorded this
25(OH)D2 AUC140
increases, p = 0.006
25(OH)D2 AUC140 was higher in daily than 2-weekly (17%, p = 0.006) and 4-weekly (20%, p = 0.001) D2-treated groups
PMID 28231782 · one of two readings recorded this
25(OH)D3 AUC140
decreases, p = 0.008
25(OH)D3 AUC140 was lower in daily than 2-weekly (11%, p = 0.002) and 4-weekly D3-treated groups (10%, p = 0.008)
PMID 28231782 · one of two readings recorded this
25(OH)D3 AUC140
decreases, p = 0.002
25(OH)D3 AUC140 was lower in daily than 2-weekly (11%, p = 0.002) and 4-weekly D3-treated groups (10%, p = 0.008)
PMID 28231782 · one of two readings recorded this
25(OH)D3 level decrease in D2-treated groups
decreases
In D2-treated groups, there was 16.4 nmol/L decrease in 25(OH)D3 level that correlated (p < 0.001) with 25(OH)D2 level increase (r = 0.48) and baseline 25(OH)D level (r = 0.58)
PMID 28231782 · one of two readings recorded this
area under the curve of serum 25(OH)D (25(OH)D2 + 25(OH)D3) from day 0 to day 140, by high performance liquid chromatography; active-treatment arms pooled D2 and D3 against placebo
increases, AUC140 40% (D3 daily) to 55% (D3 2-weekly) higher with active treatment than placebo
Not recorded as a finding: this platform holds no node for the endpoint
AUC from day 0 to 140 (AUC140) of 25(OH)D was 40% (D3 daily) to 55% (D3 2-weekly) higher with active-treatment than placebo (p < 0.001).
PMID 28231782 · one of two readings recorded this
baseline 25(OH)D as predictor of response to D2 and D3
unclear, p = 0.001
Baseline 25(OH)D level predicted response to D2 and D3 (p < 0.001)
PMID 28231782 · one of two readings recorded this
correlation of 25(OH)D3 decrease with 25(OH)D2 increase
unclear, p = 0.001
In D2-treated groups, there was 16.4 nmol/L decrease in 25(OH)D3 level that correlated (p < 0.001) with 25(OH)D2 level increase (r = 0.48) and baseline 25(OH)D level (r = 0.58)
PMID 28231782 · one of two readings recorded this
correlation of 25(OH)D3 decrease with baseline 25(OH)D
unclear, p = 0.001
In D2-treated groups, there was 16.4 nmol/L decrease in 25(OH)D3 level that correlated (p < 0.001) with 25(OH)D2 level increase (r = 0.48) and baseline 25(OH)D level (r = 0.58)
PMID 28231782 · one of two readings recorded this
incremental AUC7 of D3 and 25(OH)D3 in D3-treated groups versus D2 and 25(OH)D2 in D2-treated groups
modulates
Incremental AUC from day 0 to 7 (AUC7) of D3 and 25(OH)D3 in D3-treated groups were 118-243% higher and 31-39% lower, respectively
PMID 28231782 · one of two readings recorded this
incremental AUC7 response by sex
increases
Incremental AUC7 of D3 and 25(OH)D3 in D3-treated groups and D2 and 25(OH)D2 in D2-treated groups were higher in females than males (55, 13, 64, and 28%, respectively)
PMID 28231782 · one of two readings recorded this
serum 25(OH)D change from baseline
increases
Baseline 25(OH)D level was 39.8(11.9) and increased by 3.3(11.6) and 28.6(16.3) nmol/L, in the placebo and active-treatment groups, respectively
PMID 28231782 · one of two readings recorded this
serum 25(OH)D change from baseline
no effect
Baseline 25(OH)D level was 39.8(11.9) and increased by 3.3(11.6) and 28.6(16.3) nmol/L, in the placebo and active-treatment groups, respectively
PMID 28231782 · one of two readings recorded this
25OH-D3 dose giving serum vitamin D status similar to 10 µg vitD3
modulates
Based on the assumption that 1 µg vitD3/day will show an increase in vitamin D status of 1.96 nmol/L, the results showed that 23 µg vitD2 and 6.8 µg 25OH-D3 was similar to 10 µg vitD3
PMID 29295513 · one of two readings recorded this
increase in vitamin D status per 1 µg vitD3/day (assumed)
increases
Based on the assumption that 1 µg vitD3/day will show an increase in vitamin D status of 1.96 nmol/L, the results showed that 23 µg vitD2 and 6.8 µg 25OH-D3 was similar to 10 µg vitD3
PMID 29295513 · one of two readings recorded this
serum 25-hydroxyvitamin D (vitamin D status) by LC-MS/MS after 6 weeks each of 10 ug/day vitamin D3, 25OH-D3 and vitamin D2 in a crossover
Not recorded as a finding: the comparison was against another active treatment
The hypothesis that the three sources of vitamin D affect vitamin D status equally was rejected.
PMID 29295513 · one of two readings recorded this
vitD2 dose giving serum vitamin D status similar to 10 µg vitD3
modulates
Based on the assumption that 1 µg vitD3/day will show an increase in vitamin D status of 1.96 nmol/L, the results showed that 23 µg vitD2 and 6.8 µg 25OH-D3 was similar to 10 µg vitD3
PMID 29295513 · one of two readings recorded this
Annualised relapse rate
no effect, n = 417
Vitamin D₃ had no effect on the annualised relapse rate at 52 weeks' follow-up (rate difference -0.05, 95% CI -0.17 to 0.07; I² = 38%; five trials; 417 participants
PMID 30246874 · one of two readings recorded this
Expanded Disability Status Scale
no effect, n = 221
on the Expanded Disability Status Scale at 52 weeks' follow-up (MD -0.25, 95% CI -0.61 to 0.10; I² = 35%; five trials; 221 participants
PMID 30246874 · one of two readings recorded this
Fatigue
no effect, n = 71
The other study (71 participants) found no effect on fatigue at 96 weeks' follow-up
PMID 30246874 · one of two readings recorded this
Fatigue
decreases, n = 158
One study (158 participants) reported that vitamin D₃ reduced fatigue compared with placebo at 26 weeks' follow-up
PMID 30246874 · one of two readings recorded this
Minor adverse effects
no effect, n = 701
or minor adverse effects within a range of 26 to 96 weeks' follow-up (RD 0.02, 95% CI -0.02 to 0.06; I² = 20%; eight trials; 701 participants
PMID 30246874 · one of two readings recorded this
MRI gadolinium-enhancing T1 lesions
no effect, n = 256
on MRI gadolinium-enhancing T1 lesions at 52 weeks' follow-up (MD 0.02, 95% CI -0.45 to 0.48; I² = 12%; two trials; 256 participants
PMID 30246874 · one of two readings recorded this
Serious adverse effects
no effect, n = 621
Vitamin D₃ did not increase the risk of serious adverse effects within a range of 26 to 52 weeks' follow-up (RD 0.01, 95% CI -0.03 to 0.04; I² = 35%; eight trials; 621 participants
PMID 30246874 · one of two readings recorded this
lumbar spine BMD at week 24, between groups
increases, p = 0.042, n = 18
At week 24, the mean (SD) lumbar spine BMD was significantly greater in the study group than in the control group (p = 0.042)
PMID 31906840 · one of two readings recorded this
lumbar spine BMD
decreases, p = 0.006, n = 9
from 0.90 (0.09) g/cm3 to 0.86 (0.08) g/cm2 in the control group (p = 0.006)
PMID 31906840 · one of two readings recorded this
lumbar spine BMD
decreases, p = 0.004, n = 9
from 1.00 (0.13) g/cm2 to 0.97 (0.13) g/cm2 (p = 0.004) in the study group
PMID 31906840 · one of two readings recorded this
percentage change in total hip, lumbar spine and femoral neck BMD
no effect, n = 18
there were no significant differences in the percentage change of total hip, lumbar spine, and femoral neck BMD between both groups
PMID 31906840 · one of two readings recorded this
percentage change in total hip, lumbar spine and femoral neck bone mineral density at week 24 versus baseline
no effect
Not recorded as a finding: the intervention held more than the compound
However, there were no significant differences in the percentage change of total hip, lumbar spine, and femoral neck BMD between both groups.
PMID 31906840 · one of two readings recorded this
percentage change in total hip, lumbar spine and femoral neck bone mineral density at week 24
no effect
Not recorded as a finding: the intervention held more than the compound
However, there were no significant differences in the percentage change of total hip, lumbar spine, and femoral neck BMD between both groups.
PMID 31906840 · one of two readings recorded this
total hip BMD
decreases, p = 0.004, n = 9
from 0.87 (0.11) g/cm2 to 0.84 (0.11) g/cm2 in the control group (p = 0.004)
PMID 31906840 · one of two readings recorded this
total hip BMD
decreases, p = 0.006, n = 9
from 0.96 (0.14) g/cm2 to 0.93 (0.13) g/cm2 in the study group (p = 0.006)
PMID 31906840 · one of two readings recorded this
serum 25(OH)D2, 25(OH)D3 and 25(OH)D total over 12 weeks, liquid chromatography mass spectrometry; mushroom-derived vitamin D2 versus vitamin D3 versus placebo
+14% in 25(OH)DTOTAL with D2 by week 12
Not recorded as a finding: a direction is stated and the estimate does not support it
A net + 14% increase in 25(OH)DTOTAL was established with D2 supplementation by week 12 (p > 0.05), which was not statistically different to D3.
PMID 33176826 · one of two readings recorded this
serum 25(OH)D2
increases, p = 0.0001
D2 supplementation increased 25(OH)D2 by + 347% (7.0 ± 1.1 nmol·L- 1 to 31.4 ± 2.1 nmol·L- 1, p < 0.0001)
PMID 33176826 · one of two readings recorded this
serum 25(OH)D3
decreases, p = 0.001
resulted in a - 42% reduction in 25(OH)D3 by week 6 (p = 0.001)
PMID 33176826 · one of two readings recorded this
serum 25(OH)D3
increases, p = 0.0001
an expected rise in 25(OH)D3 concentrations from 38.8 ± 5.2 nmol·L- 1 to 82.0 ± 7.9 nmol·L- 1 (p < 0.0001)
PMID 33176826 · one of two readings recorded this
serum 25(OH)DTOTAL
no effect, p = 0.05
A net + 14% increase in 25(OH)DTOTAL was established with D2 supplementation by week 12 (p > 0.05)
PMID 33176826 · one of two readings recorded this
serum 25(OH)DTOTAL
decreases, p = 0.046
Vitamin D status was maintained with PL, following an initial - 15% reduction by week 6 (p ≤ 0.046 compared to both supplement groups)
PMID 33176826 · one of two readings recorded this
serum 25(OH)DTOTAL
increases, p = 0.0001
Vitamin D status (25(OH)DTOTAL) was significantly increased with vitamin D3 supplementation from 46.1 ± 5.3 nmol·L- 1 to 88.0 ± 8.6 nmol·L- 1 (p < 0.0001)
PMID 33176826 · one of two readings recorded this
serum total 25(OH)D (25(OH)D2 plus 25(OH)D3) by liquid chromatography mass spectrometry, baseline to week 12, mushroom-derived vitamin D2 versus vitamin D3 versus placebo
increases, +14% in 25(OH)D total with D2 by week 12
Not recorded as a finding: the result compares a group with itself, not with a control
A net + 14% increase in 25(OH)DTOTAL was established with D2 supplementation by week 12 (p > 0.05), which was not statistically different to D3.
PMID 33176826 · one of two readings recorded this
cognitive function and mood measures
no effect, n = 436
There were no significant effects of treatment on any of the measures of cognitive function or mood
PMID 33339304 · one of two readings recorded this
cognitive performance and mood measures over 24 weeks, with serum 25-OH-D, 25-OH-D2 and 25-OH-D3 as co-primary endpoints; arms were vitamin D3, vitamin D2-enhanced mushroom matrix, standard mushroom and placebo
no effect
Not recorded as a finding: this platform holds no node for the endpoint
There were no significant effects of treatment on any of the measures of cognitive function or mood.
PMID 33339304 · one of two readings recorded this
serum total 25-OH-D and 25-OH-D3
decreases, p = 0.05
Levels of total 25-OH-D and 25-OH-D3 were maintained in the D3 arm but decreased significantly (p < 0.05) in the remaining arms (D2M, SM and PL)
PMID 33339304 · one of two readings recorded this
serum total 25-OH-D and 25-OH-D3
no effect
Levels of total 25-OH-D and 25-OH-D3 were maintained in the D3 arm but decreased significantly (p < 0.05) in the remaining arms (D2M, SM and PL)
PMID 33339304 · one of two readings recorded this
ambulatory status: independent without gait aid
no effect, p = 0.514, n = 119
- Independent without gait aid | 28 (45.9) | 21 (36.2) | 0.514
PMID 33478397 · one of two readings recorded this
ambulatory status: pick up walker
no effect, n = 119
- Pick up walker | 20 (32.8) | 22 (37.9)
PMID 33478397 · one of two readings recorded this
ambulatory status: single cane
no effect, n = 119
- Single cane | 5 (8.2) | 5 (8.6)
PMID 33478397 · one of two readings recorded this
ambulatory status: tripod cane
no effect, n = 119
- Tripod cane | 0 (0.0) | 2 (3.4)
PMID 33478397 · one of two readings recorded this
ambulatory status: wheel chair
no effect, n = 119
- Wheel chair | 2 (3.3) | 4 (6.9)
PMID 33478397 · one of two readings recorded this
Barthel Index and EQ-VAS, difference between groups
no effect, n = 119
However, there was no significant difference when comparing between the 2 groups
PMID 33478397 · one of two readings recorded this
corrected serum calcium, baseline to 12 weeks
increases, p = 0.001
8.8 ± 0.4 mg/dL to 9.3 ± 0.5 mg/dL in the low-dose group, p < 0.001
PMID 33478397 · one of two readings recorded this
corrected serum calcium, baseline to 12 weeks
increases, p = 0.001
8.8 ± 0.6 mg/dL to 9.2 ± 0.6 mg/dL in the high-dose group, p < 0.001
PMID 33478397 · one of two readings recorded this
functional status: bed bound
no effect, p = 0.374, n = 119
- Bed bound | 6 (9.8) | 4 (6.9) | 0.374
PMID 33478397 · one of two readings recorded this
functional status: indoor
no effect, n = 119
- Indoor | 14 (23.0) | 19 (32.8)
PMID 33478397 · one of two readings recorded this
functional status: outdoor
no effect, n = 119
- Outdoor | 41 (67.2) | 35 (60.3)
PMID 33478397 · one of two readings recorded this
post-treatment serum 25(OH)D, between-group difference
increases, p = 0.001, n = 119
There was a significant difference in the post-treatment level of serum 25(OH)D between the 2 groups (p < 0.001)
PMID 33478397 · one of two readings recorded this
proportion achieving optimal serum 25(OH)D level
increases, p = 0.001, n = 119
The number of patients who achieved optimal serum 25(OH)D level was greater in the high-dose group significantly (82.8 and 52.5% for the high- and low-dose groups, respectively; p < 0.001)
PMID 33478397 · one of two readings recorded this
serum 25(OH)D at 12 weeks
increases, n = 119
the mean serum 25(OH)D levels significantly increased to 31.4 ± 8.8 and 40.5 ± 12.5 ng/mL in the low- and high-dose groups, respectively
PMID 33478397 · one of two readings recorded this
serum 25(OH)D at baseline
no effect, p = 0.249
Baseline mean serum 25(OH)D levels in the low- and high-dose groups were 20.2 ± 8.2 ng/mL and 18.1 ± 11.1 ng/mL, respectively (p = 0.249)
PMID 33478397 · one of two readings recorded this
serum 25(OH)D concentration at 12 weeks, electrochemiluminescence binding assay on a cobas 8000 analyzer; proportion reaching serum 25(OH)D above 30 ng/mL
31.4 vs 40.5 ng/mL in the low- and high-dose groups
Not recorded as a finding: the comparison was against another active treatment
At the completion of the study, the mean serum 25(OH)D levels significantly increased to 31.4 ± 8.8 and 40.5 ± 12.5 ng/mL in the low- and high-dose groups, respectively.
PMID 33478397 · one of two readings recorded this
serum PTH at 12 weeks
no effect
51.8 ± 36.0 pg/mL in the low-dose group, and 56.6 ± 55.5 pg/mL in the high-dose group
PMID 33478397 · one of two readings recorded this
serum PTH at baseline
The baseline mean serum PTH levels were 41.3 ± 18.4 pg/mL and 50.8 ± 25.3 pg/mL in the low- and high-dose groups, respectively
PMID 33478397 · one of two readings recorded this
change in serum total 25(OH)D, 25(OH)D2 and 25(OH)D3 (nmol/L) and serum PTH, ergocalciferol versus cholecalciferol in apparently healthy adults, 22 studies pooled
cholecalciferol minus ergocalciferol total 25(OH)D MD 15.69 nmol/L (95% CI 9.46 to 21.93)
Not recorded as a finding: the comparison was against another active treatment
On pooling results of the included studies, we found that cholecalciferol intervention elevated total 25(OH)D levels to a greater extent (p < 0.05) as compared to ergocalciferol (mean difference (MD): 15.69 nmol/L, 95% CI: 9.46 to 21.93).
PMID 34684328 · one of two readings recorded this
Serum 25(OH)D2
decreases
Ergocalciferol intervention resulted in significantly higher 25(OH)D2 (MD: −27.5 nmol/L (95% CI: −34.24 to −20.76)
PMID 34684328 · one of two readings recorded this
Serum 25(OH)D3
increases, p = 0.05
cholecalciferol intervention elevated 25(OH)D3 to a significantly greater extent (MD: 40.85 nmol/L, 95% CI: 31.52 to 50.17, p < 0.05 nmol/L)
PMID 34684328 · one of two readings recorded this
Serum parathyroid hormone (PTH)
decreases, p = 0.005
Meta-analysis suggested higher efficacy of cholecalciferol in reducing PTH levels than ergocalciferol (MD: −0.56 pmol/L; 95% CI: −0.93 to −0.18, p = 0.005)
PMID 34684328 · one of two readings recorded this
Serum parathyroid hormone (PTH)
decreases, p = 0.04
Subgroup analysis in seven studies with daily intervention reduced heterogeneity (I2 = 0), as well as the magnitude of effect (MD = −0.15 pmol/L, 95% CI: −0.01 to −0.3, p = 0.04)
PMID 34684328 · one of two readings recorded this
serum total 25(OH)D, 25(OH)D2, 25(OH)D3 and serum PTH, ergocalciferol (vitamin D2) versus cholecalciferol, mean difference
decreases, cholecalciferol raised total 25(OH)D more than ergocalciferol, MD 15.69 nmol/L (95% CI 9.46 to 21.93)
Not recorded as a finding: the comparison was against another active treatment
On pooling results of the included studies, we found that cholecalciferol intervention elevated total 25(OH)D levels to a greater extent (p < 0.05) as compared to ergocalciferol (mean difference (MD): 15.69 nmol/L, 95% CI: 9.46 to 21.93).
PMID 34684328 · one of two readings recorded this
Serum total 25(OH)D
increases, p = 0.05, n = 1277
cholecalciferol intervention elevated total 25(OH)D levels to a greater extent (p < 0.05) as compared to ergocalciferol (mean difference (MD): 15.69 nmol/L, 95% CI: 9.46 to 21.93)
PMID 34684328 · one of two readings recorded this
Serum total 25(OH)D
increases
reduced heterogeneity (I2 = 67%) as well as the effect size (MD: 9.62 nmol/L, 95% CI: 5.82 to 13.43)
PMID 34684328 · one of two readings recorded this
Serum total 25(OH)D
increases
when compared to the studies which provided a single bolus dose (MD: 25.06 nmol/L, 95% CI: 3.92 to 46.19)
PMID 34684328 · one of two readings recorded this
arterial stiffness by pulse wave velocity (mixed a-PWv, cf-PWv, ba-PWv and other types pooled), network meta-analysis; the only vitamin D2 contrast stated is against vitamin D3
vitamin D3 versus vitamin D2 ES -0.25 (95% CI -0.48, -0.02)
Not recorded as a finding: the comparison was against another active treatment
In addition, oral vitamin D3 supplementation proved to be a better supplement for decreasing arterial stiffness than vitamin D2 supplementation (ES: −0.25; 95% CI: −0.48, −0.02; −36.0% m/s).
PMID 35267985 · one of two readings recorded this
Arterial stiffness (pulse wave velocity)
decreases
for interventions >12 weeks (ES: −0.15; 95% CI: −0.30, −0.00; −60.0% m/s; and ES: −0.25; 95% CI: −0.48, −0.02, −52.0% m/s, respectively)
PMID 35267985 · one of two readings recorded this
Arterial stiffness (pulse wave velocity)
decreases
oral vitamin D3 supplementation proved to be a better supplement for decreasing arterial stiffness than vitamin D2 supplementation (ES: −0.25; 95% CI: −0.48, −0.02; −36.0% m/s)
PMID 35267985 · one of two readings recorded this
Arterial stiffness (pulse wave velocity)
decreases
central PWv showed significant results in oral supplementation with vitamin D3, compared with oral supplementation with vitamin D2 (ES: −0.25; 95% CI: −0.48, −0.02; −36.0% m/s)
PMID 35267985 · one of two readings recorded this
Arterial stiffness (pulse wave velocity)
decreases
for interventions >12 weeks (ES: −0.15; 95% CI: −0.30, −0.00; −60.0% m/s; and ES: −0.25; 95% CI: −0.48, −0.02, −52.0% m/s, respectively)
PMID 35267985 · one of two readings recorded this
Arterial stiffness (pulse wave velocity)
decreases
oral supplementation with vitamin D3 was effective in reducing arterial stiffness, compared with oral supplementation with vitamin D2 in adults <65 years (ES: −0.30; 95% CI: −0.57, −0.03; −58.0% m/s)
PMID 35267985 · one of two readings recorded this
Arterial stiffness PWv % change
no effect
Dreyer et al., 2014 | United Kingdom | IG: 20 (39.1) CG: 18 (26.3) | IG: 45.8 ± 10.0 CG: 48.8 ± 12.2 | CKD | Ergocalciferol (vit. D2) | 50,000 IU (weekly for one month) + 50,000 IU (monthly) | 16 | a-PWv | Vicorder | IG: 8.5 ± 1.1 CG: 8.5 ± 1.5 | IG: −1.2% CG: 0.0%
PMID 35267985 · one of two readings recorded this
Arterial stiffness PWv % change
unclear
Kovesdy et al., 2012 | United States | IG1: 40 (0.0) IG2: 40 (2.0) | IG1: 67.6 ± 9.3 IG2: 69.3 ± 10.6 | CKD | IG1: Ergocalciferol (vit. D2) IG2: Cholecalciferol (vit. D3) | IG1: 50,000 IU (single dose) IG2: 1 or 2 µg (daily) | 16 | a-PWv | Sphygmocor | IG1: 12.8 ± 3.5 IG2: 13.5 ± 3.9 | IG1: 1.6% IG2: −1.5%
PMID 35267985 · one of two readings recorded this
Arterial stiffness PWv % change
unclear
Forouhi et al., 2016 | United Kingdom | IG1: 112 (43.8) IG2: 114 (43.0) CG: 114 (42.1) | IG1: 53.5 ± 8.7 IG2: 52.5 ± 8.2 CG: 52.4 ± 8.5 | Pre-DM2 | IG1: Ergocalciferol (vit. D2) IG2: Cholecalciferol (vit. D3) | IG1: 3300 IU (daily) IG2: 3300 IU (daily) | 16 | cf-PWv | Doppler MDII | IG1: 7.3 ± 2.7 IG2: 7.9 ± 2.0 CG: 7.4 ± 2.0 | IG1: −2.3% IG2: −9.5% CG: 4.9%
PMID 35267985 · one of two readings recorded this
Probability of being the best intervention for arterial stiffness
decreases
Oral supplementation with vitamin B9 was more likely to be the best (31.0%)
PMID 35267985 · one of two readings recorded this
SUCRA value for arterial stiffness reduction
decreases
oral supplementation with vitamin D3 showed a higher SUCRA value (78.0%)
PMID 35267985 · one of two readings recorded this
differentially expressed genes in blood transcriptome, overlap between vitamin D2 and D3
modulates
most changes were specific to either one vitamin or the other
PMID 35281034 · one of two readings recorded this
direction of gene expression change after vitamin D3
decreases
following vitamin D3 supplementation, the majority of changes in gene expression reflected a down-regulation in the activity of genes
PMID 35281034 · one of two readings recorded this
ethnic differences in transcriptome response
unclear
The data also pointed to the possibility of ethnic differences in the responses
PMID 35281034 · one of two readings recorded this
type I and type II interferon-associated gene expression
increases
gene expression associated with type I and type II interferon activity, critical to the innate response to bacterial and viral infections, differed following supplementation with either vitamin D2 or vitamin D3, with only vitamin D3 having a stimulatory effect
PMID 35281034 · one of two readings recorded this
Breast milk 25OHD concentration, supplemented vs not supplemented mothers
no effect
a significant increase was found in breast milk of mothers receiving vitamin D supplementation in vitamin D3 (MD: 28 IU/L, 95% CI: 6, 50), and ARA (MD: 53, 95% CI: 28, 77), but not vitamin D (MD: 4, 95% CI: -1, 9) or 25OHD (MD: 9, 95% CI: -14, 32)
PMID 37264448 · one of two readings recorded this
Breast milk calcium concentration, calcium supplementation vs control
no effect
no significant differences were found between groups of calcium supplementation (mean difference (MD): 4.8 mg/L, 95% CI: -4.4, 14.1)
PMID 37264448 · one of two readings recorded this
Breast milk calcium concentration
decreases, p = 0.008
women with conditions 203 mg/L, 95% CI: 171, 234, healthy women 257 mg/L, 95% CI: 232, 281, p = 0.008
PMID 37264448 · one of two readings recorded this
Breast milk total antirachitic activity (ARA), supplemented vs not supplemented mothers
increases
a significant increase was found in breast milk of mothers receiving vitamin D supplementation in vitamin D3 (MD: 28 IU/L, 95% CI: 6, 50), and ARA (MD: 53, 95% CI: 28, 77), but not vitamin D (MD: 4, 95% CI: -1, 9) or 25OHD (MD: 9, 95% CI: -14, 32)
PMID 37264448 · one of two readings recorded this
Breast milk total ARA by season
modulates
total ARA summer: 117 IU/L, 95% CI: 108, 126, fall: 63 IU/L, 95% CI: 52, 73, winter: 66 IU/L, 95% CI: 45, 87, spring: 58 IU/L, 95% CI: 50, 66
PMID 37264448 · one of two readings recorded this
Breast milk total ARA by vitamin D supplementation status
increases
total ARA: 91 IU/L, 95% CI: 73, 109 vs. 48 IU/L, 95% CI: 34, 63
PMID 37264448 · one of two readings recorded this
Breast milk vitamin D concentration, supplemented vs not supplemented mothers
no effect
a significant increase was found in breast milk of mothers receiving vitamin D supplementation in vitamin D3 (MD: 28 IU/L, 95% CI: 6, 50), and ARA (MD: 53, 95% CI: 28, 77), but not vitamin D (MD: 4, 95% CI: -1, 9) or 25OHD (MD: 9, 95% CI: -14, 32)
PMID 37264448 · one of two readings recorded this
Breast milk vitamin D3 concentration, supplemented vs not supplemented mothers
increases
a significant increase was found in breast milk of mothers receiving vitamin D supplementation in vitamin D3 (MD: 28 IU/L, 95% CI: 6, 50), and ARA (MD: 53, 95% CI: 28, 77), but not vitamin D (MD: 4, 95% CI: -1, 9) or 25OHD (MD: 9, 95% CI: -14, 32)
PMID 37264448 · one of two readings recorded this
Breast milk zinc concentration, zinc supplementation vs control
no effect
no significant differences were found between levels of zinc supplementation (MD: 0.11, 95% CI: -0.18, 0.40)
PMID 37264448 · one of two readings recorded this
hemoglobin
no effect
No significant changes in hemoglobin were observed
PMID 37375660 · one of two readings recorded this
age at baseline
The mean age was 28.7 ± 10.7 mo
PMID 37375660 · one of two readings recorded this
baseline dietary vitamin D intake
At baseline, the mean VD intake was 99.7 ± 183.7 IU/day
PMID 37375660 · one of two readings recorded this
correlation between iPTH and 25(OH)D
decreases, p = 0.05
The correlation between iPTH and 25-OH-D was between −0.16 and −0.15 at baseline and after three months (p < 0.05)
PMID 37375660 · one of two readings recorded this
prevalence of vitamin D deficiency
decreases
The prevalence of VD deficiency decreased in all three VD-supplemented groups, with the largest effect observed in the 1000 IU D3 group
PMID 37375660 · one of two readings recorded this
serum 25(OH)D change over three months
increases
There was a significant and positive change in serum 25-OH-D concentrations over three months of the trial among children in each of the three VD groups but not in the MM non-VD group
PMID 37375660 · one of two readings recorded this
serum 25(OH)D concentration, chemiluminescent microparticle assay (CMIA, Architect analyzer), change over three months
increases
Not recorded as a finding: the result compares a group with itself, not with a control
There was a significant and positive change in serum 25-OH-D concentrations over three months of the trial among children in each of the three VD groups but not in the MM non-VD group (Table 2).
PMID 37375660 · one of two readings recorded this
serum 25(OH)D, other pairwise comparisons, largest change in 1000 IU D3 group
increases
with the largest change in the 1000 IU D3 group, followed by the 800 IU D2 group
PMID 37375660 · one of two readings recorded this
serum 25(OH)D, pairwise comparison of 400 IU D2 versus 800 IU D2
no effect
For 25-OH-D, no difference was observed between the 400 IU D2 and the 800 IU D2 groups
PMID 37375660 · one of two readings recorded this
serum iPTH
decreases
A statistically-significant decrease was observed in iPTH concentrations for the three VD-supplemented groups but not in the MM non-VD group
PMID 37375660 · one of two readings recorded this
supplement compliance rate
On average, the compliance rate was 75.8% ± 15.1% considering the total days of supplement consumption
PMID 37375660 · one of two readings recorded this
change in serum total 25(OH)D, 25(OH)D2 and 25(OH)D3 concentration, vitamin D2 versus vitamin D3 daily or weekly dosing; LC-MS/MS WMD and other methods pooled as SMD
decreases, SMD -0.76 (95% CI -1.01, -0.50), smaller change in total 25(OH)D with vitamin D2 than vitamin D3
Not recorded as a finding: the comparison was against another active treatment
As shown in Figure 2, the SMD of the meta-analysis was −0.76 (95% CI: −1.01, −0.50; I 2 = 72%; P < 0.00001) indicating a smaller change in total 25(OH)D in the vitamin D2 group compared with the vitamin D3 group.
PMID 37865222 · one of two readings recorded this
change in serum total 25(OH)D (and 25(OH)D2, 25(OH)D3), vitamin D2 versus vitamin D3, SMD or WMD by LC-MS/MS
decreases, SMD -0.76 (95% CI -1.01, -0.50; I2 = 72%), smaller rise in total 25(OH)D with D2 than D3
Not recorded as a finding: the comparison was against another active treatment
As shown in Figure 2, the SMD of the meta-analysis was −0.76 (95% CI: −1.01, −0.50; I 2 = 72%; P < 0.00001) indicating a smaller change in total 25(OH)D in the vitamin D2 group compared with the vitamin D3 group.
PMID 37865222 · one of two readings recorded this
Change in total 25(OH)D (weighted mean difference, LC-MS/MS studies)
decreases, p = 0.00001
compared with −13.77 nmol/L (95% CI: −16.75, −10.79 nmol/L; I 2 = 11%; P < 0.00001) in subjects predominantly with healthy weight
PMID 37865222 · one of two readings recorded this
Change in total 25(OH)D (weighted mean difference, LC-MS/MS studies)
no effect, p = 0.75
MD of the vitamin D2-vitamin D3 comparison in subjects predominantly with overweight of 0.98 nmol/L (95% CI: −5.14, 7.10 nmol/L; I 2 = 0%; P = 0.75)
PMID 37865222 · one of two readings recorded this
Change in total 25(OH)D (weighted mean difference)
no effect, p = 0.05
Excluding the studies classified as being of “high risk” of bias, the MD changed to −7.27 (95% CI: −14.67, 0.14; I 2 = 77%; P = 0.05)
PMID 37865222 · one of two readings recorded this
Change in total 25(OH)D (weighted mean difference)
decreases, p = 0.00001
Only studies analyzed using HPLC-MS/MS | | −10.39 nmol/L | −14.62, −6.16 | <0.00001 | 64 | 293/306
PMID 37865222 · one of two readings recorded this